Business
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March
BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated,
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (\"Tonix\" or the \"Company\"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026: TD Cowen 46th Annual Healthcare ConferenceCompany PresentationPresenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate: Wednesday March 4, 2026Place: Boston Marriott Copley PlaceTime: 11:10 AM – 11:40 AM ETRoom: MIT, 3rd Floor Barclays 28th Annual Healthcare Conference Company ParticipationManagement will be available for 1x1 meetings, March 10 - 12, at the Loews Miami South Beach Hotel If you are interested in meeting with Tonix Pharmaceuticals at any of these conferences, please reach out to your respective TD Cowen and Barclays representatives. A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website at https://ir.tonixpharma.com/news-events. A replay of the webcast will be accessible for 90 days following the event. Tonix Pharmaceuticals Holding Corp.Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking StatementsCertain statements in this press release...